SAM
MDGL icon

Silvercrest Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Silvercrest Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Sell
15,655
-308
-2% -$158K 0.06% 381
2026
Q1 		$8.36M Buy
+15,963
New +$7.63M 0.06% 338

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Silvercrest Asset Management's MDGL Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 1.9% in Q2 2026, selling an estimated $158K and leaving 15,655 shares worth $8.41M. The position accounts for 0.06% of the portfolio, ranked #381.

Silvercrest Asset Management first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Silvercrest Asset Management held 15,655 shares of Madrigal Pharmaceuticals worth $8.41M as of Q2 2026.
  • Silvercrest Asset Management sold 308 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $158K.
  • Madrigal Pharmaceuticals made up 0.06% of Silvercrest Asset Management's portfolio in Q2 2026, its #381 holding.
  • Silvercrest Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.